Cancer Research AACR Legacy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 1760, March 15, 2008. doi: 10.1158/0008-5472.CAN-07-3177
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Danes, C. G.
Right arrow Articles by Yu, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danes, C. G.
Right arrow Articles by Yu, D.

Cell, Tumor, and Stem Cell Biology

14-3-3{zeta} Down-regulates p53 in Mammary Epithelial Cells and Confers Luminal Filling

Christopher G. Danes1,2, Shannon L. Wyszomierski1, Jing Lu1,2, Christopher L. Neal1, Wentao Yang1 and Dihua Yu1

1 Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center; 2 The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas

Requests for reprints: Dihua Yu, Department of Molecular and Cellular Oncology, Unit 108, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3636; E-mail: dyu{at}mdanderson.org.

Key Words: 14-3-3{zeta} • p53 • anoikis • luminal filling • early stage breast cancer

Recent progress in diagnostic tools allows many breast cancers to be detected at an early preinvasive stage. Thus, a better understanding of the molecular basis of early breast cancer progression is essential. Previously, we discovered that 14-3-3{zeta} is overexpressed in >40% of advanced breast cancers, and this overexpression predicts poor patient survival. Here, we examined at what stage of breast disease 14-3-3{zeta} overexpression occurs, and we found that increased expression of 14-3-3{zeta} begins at atypical ductal hyperplasia, an early stage of breast disease. To determine whether 14-3-3{zeta} overexpression is a decisive early event in breast cancer, we overexpressed 14-3-3{zeta} in MCF10A cells and examined its effect in a three-dimensional culture model. We discovered that 14-3-3{zeta} overexpression severely disrupted the acini architecture resulting in luminal filling. Proper lumen formation is a result of anoikis, apoptosis due to detachment from the basement membrane. We found that 14-3-3{zeta} overexpression conferred resistance to anoikis. Additionally, 14-3-3{zeta} overexpression in MCF10A cells and in mammary epithelial cells (MEC) from 14-3-3{zeta} transgenic mice reduced expression of p53, which is known to mediate anoikis. Mechanistically, 14-3-3{zeta} induced hyperactivation of the phosphoinositide 3-kinase/Akt pathway which led to phosphorylation and translocation of the MDM2 E3 ligase resulting in increased p53 degradation. Ectopic expression of p53 restored luminal apoptosis in 14-3-3{zeta}–overexpressing MCF10A acini in three-dimensional cultures. These data suggest that 14-3-3{zeta} overexpression is a critical event in early breast disease, and down-regulation of p53 is one of the mechanisms by which 14-3-3{zeta} alters MEC acini structure and increases the risk of breast cancer. [Cancer Res 2008;68(6):1760–7]




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. L. Neal, J. Yao, W. Yang, X. Zhou, N. T. Nguyen, J. Lu, C. G. Danes, H. Guo, K.-H. Lan, J. Ensor, et al.
14-3-3{zeta} Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival
Cancer Res., April 15, 2009; 69(8): 3425 - 3432.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.